8-K filing — Immix Biopharma, Inc. (IMMX)
Filed: 2026-09-30 AccNo: 0001493152-26-045143 Size: 558 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19
Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight and lowers the price target from $20 to $19.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading